BridgeBio Pharma, Inc.

BBIO

Explore Our Financial Data > Companies > BridgeBio Pharma, Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
BBIO
CIK0001743881
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304
Website bridgebio.com
Phone(650) 391-9740
CEONeil Kumar
Employees400

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$127.42 million
Pre-Tax Income$-675.64 million
Net Income$-676.80 million
Net Income to Common$-667.97 million
EPS$-3.56
View All
Balance Sheet
Cash$540.60 million
Assets$881.64 million
Liabilities$2.52 billion
Common Equity$-1.65 billion
Liabilities & Equity$881.64 million
View All
Cash Flow Statement
Net Income$-676.80 million
Cash From Operating Activities$-500.42 million
Cash From Investing Activities$36.43 million
Cash From Financing Activities$529.24 million
Change in Cash$65.25 million
View All
Calculations
NOPAT$-488.38 million
EBITDA$-680.90 million
Price to EarningsN/A
Price to BookN/A
ROE50.59%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Article Link

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.

The biotech sector is facing a pivotal moment, after a frustrating year of stalled rallies. A look at the widely followed industry benchmark exchange-traded fund (ticker: XBI) shows just how frustrating price action has been for investors so far in 2025.

Article Link

Peloton upgraded, Booking downgraded: Wall Street's top analyst calls

Peloton upgraded, Booking downgraded: Wall Street's top analyst calls

Article Link

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?

BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Article Link

Truist Sees Upside in BridgeBio Pharma’s (BBIO) ATTR-CM Strategy

BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 21, Truist Securities initiated coverage of BBIO with a Buy rating and a $66 price target, spotlighting the promising launch of Attruby for treating ATTR-CM. Citing its growing use as a first-line therapy due to […]

Article Link